|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Brain Tumors
Tumors that begin in brain tissue are known as primary tumors of the brain. Primary brain tumors are named according to the type of cells or the part of the brain in which they begin. The most common primary brain tumors are gliomas. They begin in glial cells. There are many types of gliomas such as Astrocytoma which is a tumor that arises from star-shaped glial cells called astrocytes. In adults, astrocytomas most often arise in the cerebrum. In children, they occur in the brain stem, the cerebrum, and the cerebellum. A grade III astrocytoma is sometimes called an anaplastic astrocytoma. A grade IV astrocytoma is usually called a glioblastoma multiforme.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Tuberous Sclerosis (SEGA Lesions) Study - M2301
The purpose of this research study is to learn if a Novartis investigational drug is effective at shrinking or slowing the growth of SEGA lesions in patients with tuberous sclerosis. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 3 Participation Duration: Eligible participants will be required to visit the study center every 2 weeks during the first 2 months, then every 4 to 12 weeks until the end of the trial. Protocol Number: CRAD001M2301 Tuberous Sclerosis (Kidney Lesions) Study - M2302
The goal of this clinical research study is to learn if a Novartis investigational drug can shrink or slow the growth of kidney lesions in patients with tuberous sclerosis (TS) or lymphangioleiomyomatosis (LAM). An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 3 Participation Duration: Participants will be required to visit the study center once every 2 weeks during the first 2 months, then every 4-6 weeks until week 24. After week 24, visits will occur once every 12 weeks until the study is completed. Protocol Number: CRAD001M2302 |